Kimmtrak (Tebentafusp-Tebn) for Melanoma

Overview
Kimmtrak is a medication that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults living with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. Unresectable means the cancer can’t be removed with surgery, and metastatic means it has spread from the eye to other parts of the body. Uveal melanoma is a type of melanoma that occurs in the eye and is challenging to treat. Kimmtrak is also known by its drug name, tebentafusp-tebn.

Kimmtrak is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. This means that it’s designed to target a protein called gp100 found in cancer cells and another protein called CD3 found in immune cells. Kimmtrak works by getting T cells to attack melanoma cells.

How do I take it?
Kimmtrak is delivered intravenously, meaning it is given through a vein. It’s administered at a hospital or infusion center.

Side effects
The FDA-approved label for Kimmtrak lists common side effects including rash, itching, fatigue, nausea, chills, abdominal pain, swelling, hypotension (low blood pressure), dry skin, headache, and vomiting.

Rare but serious side effects include cytokine release syndrome (fever, chills, fatigue), skin reactions, elevated liver enzymes, and possible harm to the developing baby during pregnancy.

For more details about this treatment, visit:

Label: Kimmtrak — Tebentafusp Injection, Solution, Concentrate — DailyMed

Kimmtrak Prescribing Information — Immunocore